Analysis of CCND3 mutations in diffuse large B-cell lymphoma.

Area of Science:

• Oncology
• Genetics
• Hematology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a common lymphoma with a 60% cure rate.
• The prognostic role of CCND3 mutations in DLBCL is not well-established.
• Previous studies suggested a negative association in Burkitt lymphoma.

Purpose of the Study:

• To investigate the prognostic implications of CCND3 mutations in DLBCL.
• To identify potential therapeutic targets based on mutation status.

Main Methods:

• Evaluated CCND3 mutation status in 2059 DLBCL patient samples from integrated databases and 167 from a local cohort (JSPH).
• Utilized next-generation sequencing (NGS) for pathway analysis in the JSPH cohort.
• Applied the LymphGen algorithm for DLBCL subtype classification.

Main Results:

• CCND3 mutations were found in 5.5% of the integrated cohort, with hotspots at P284, R271, I290, and Q276.
• CCND3 mutations were associated with decreased overall survival (OS) in the integrated cohort (P=0.0407).
• EZB subtype DLBCL patients with CCND3 mutations showed significantly poorer OS (P=0.0140).
• Cell cycle and DNA replication pathways were upregulated in patients with CCND3 mutations.

Conclusions:

• CCND3 mutations represent a novel prognostic factor in DLBCL.
• Personalized therapeutic strategies targeting CCND3 mutations may improve DLBCL patient outcomes.